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of the Italian health care system. The following direct medical
care costs were considered: drug costs (cost to the hospital at the
dosage range reported in the SPC), administration costs (medical
devices for deferoxamine, hospital cost), laboratory assessments
(cost of laboratory exams from SPC, using hospital reimburse-
ment tariff). All costs are expressed as Euros (year 2007 values).
We considered the patients with beta thalassaemia major that
live in the Veneto region. RESULTS: According to the Regional
Rare Diseases Register, in Veneto 170 patients are affected
by thalassaemia. 153 are eligible for deferasirox treatment.
Switching all patients from deferoxamine (estimated annual
costs: €734,808–1,327,797), to deferasirox (estimated annual
costs: €3,615,382–5,575,618), would cause an expenditure
increase of €2,881,074–4,247,823/year. From drug utilization
data, it is estimated that about 15 patients with beta-talassemia
are treated with deferiprone. In this scenario, the budget impact
of switching all patients to deferasirox would be €2,858,547–
4,283,481. CONCLUSIONS: Besides the advantage of the oral
administration instead of continous subcutaneous infusion by
pump, the impact of deferasirox on the regional budget is rel-
evant. Alternative scenarios may take into account switching to
the new drug only patients subgroups (e.g., patients who do not
respond to deferoxamine) or patients for whom quality of life is
strongly affected by the infusion pump.
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OBJECTIVES: The budget impact of introducing OROS® hydro-
morphone once-daily, a novel therapy for treating patients with
severe chronic cancer and non-cancer pain, was determined in
the German health care system. METHODS: The perspective of
the social health insurance over a one-year time horizon was
adopted. An Excel® based hypothetical budget impact model
calculating the cost consequences of using strong opioids (WHO
step III) was developed. The model accounts for the costs of
opioids, breakthrough pain and adverse events. Patient numbers
are calculated using epidemiological data from the literature;
adverse event rates are based on literature. Comparators
included sustained-release (SR) morphine (twice-daily),
controlled-release (CR) oxycodone (twice-daily), hydromor-
phone (twice-daily), transdermal fentanyl and transdermal
buprenorphine. Initial prescription share of OROS® hydromor-
phone was 2.4% (October 2007 MAT). This share was hypo-
thetically extended to 8%. It was assumed that this increase in
prescription of OROS® hydromorphone is gained by switching
patients from their previous medication to OROS® hydromor-
phone (proportionally to the prescription share of the compara-
tor at start). Titration and maintenance dosing schemes taken
from previous analyses are used to model the switch. Morphine
equivalence of hydromorphone was chosen according to SmPC.
RESULTS: The number of patients treated was estimated to be
882,347 per year. The model predicted that the introduction of
OROS® HM would lower the per patient drug cost from €684.28
to €679.52 (2008 public prices). The model also predicts that
as the use of OROS® HM increases, the total budget for
strong opioids decreases. If the prescription share of OROS® HM
increased to 8% the total budget for strong opioids would
decrease by €4,199,327. CONCLUSIONS: Our analysis suggests
that under current circumstances the use of OROS® hydromor-
phone to treat patients with severe chronic pain will reduce the
overall budget spent on strong opioids.
PSY10
ESTIMATION OFTHE COSTS FOR A HEREDITARY
HEMOCHROMATOSIS GENETIC SCREENING PROGRAMME
PER 100.000 INDIVIDUALS UNDER 30YEARS OF AGE IN SPAIN
Saz-Parkinson Z1,Amate JM1,Ayuso C2
1Instituto de Salud Carlos III, Madrid, Spain, 2Fundación Jiménez Díaz,
Madrid, Spain
OBJECTIVES: Study costs of carrying out a genetic screening
programme per 100.000 individuals from the Spanish population
under 30 years of age for Hereditary Hemochromatosis (HH),
based on the calculated penetrance of HH in the South-West
Healthcare Area 11 of Madrid, and the published prevalence of
the HH genotype in Spain. METHODS: Retrospective cross-
sectional study of HFE genotyping requests from a subpopula-
tion in South West Madrid pre-screened for high ferritin values,
between January 2000 and June 2006. Based on our population’s
genotype and phenotype, clinical penetrance was calculated in a
previous study. Costs, extracted from a Spanish Medical Cost
database (SOYKOS), involved in treatment of HH-associated
diseases, biochemical testing, genetic testing, treatment of phe-
notypical HH patients and follow up were analysed to compare
the costs for genetic screening versus no screening. RESULTS:
From our data, for the main HH-associated diseases, we have
previously calculated a clinical penetrance, for HH genotype, in
the population studied, of 1.11%, compared to 0.08% for those
with wild-type HFE genotype. The main HH-associated patholo-
gies considered are hepatopathy, diabetes and arthropathy. Cost
for genetic testing of 100,000 Spanish individuals under 30 years
of, biochemical follow up of those with HH genotype, and treat-
ment of those with HH genotype and phenotype amounts to
€1,808,353.29, equivalent to €1433.49/case with HH geno-
type detected and €129,168.09 per phenotypical case with HH
genotype detected. Treatment of HH-associated pathologies,
if no other preventive intervention is undertaken (biochemical
monitoring, preventive phlebotomy treatment), would cost
€407,043.70. CONCLUSIONS: The extremely low penetrance
of HH-associated pathologies related to the HH genotype, sug-
gests that a genetic screening programme for the population
proposed is not economically justiﬁed for the Spanish National
Healthcare System. However, this does not exclude genetic
screening of ﬁrst degree relatives of HH patients and their
subsequent biochemical follow-up which could prove to be
appropriate.
PSY11
EONOMIC EVALUATION OF ETANERCEPT COMPAREDTO NO
SYSTEMICTHERAPY INTHE MANAGEMENT OF LESS SEVERE
CHRONIC PLAQUE PSORIASIS INTHE UK
Webber JM1, Lloyd AC1, Lebmeier M2, Conway P3,Warburton J2
1IMS Health, London, UK, 2Wyeth Pharmaceuticals, Maidenhead, UK,
3Wyeth Europa, Berkshire, UK
OBJECTIVES: NICE has recommended etanercept for use in
patients with severe chronic plaque psoriasis, deﬁned as a Pso-
riasis Area and Severity Index (PASI) of 10 or more and a
Dermatology Life Quality Index (DLQI) of more than 10. This
study assessed the cost-effectiveness of intermittent therapy with
etanercept 25 mg twice weekly (biw) or 50 mg biw compared
with no systemic therapy (NST) in patients with less severe
disease. METHODS: An economic model was constructed to
estimate the incremental cost per quality adjusted life year
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(QALY) for etanercept compared with NST. Patients considered
had chronic plaque psoriasis, PASI of 10–12 and any DLQI value
at baseline. Response rates were taken from a pooled analysis of
three studies of etanercept. Utility gain associated with response
was assessed using patient level DLQI change mapped to EQ5D.
Clinical and quality of life outcomes were extrapolated to a time
horizon of ten years. Costs were estimated from a UK payer
perspective including drug cost, administration visits and hospi-
tal stay for treatment failures. Probabilistic sensitivity analysis
was undertaken. RESULTS: The model estimated incremental
cost per QALY gained compared with NST to be: £2,850 (95%
CI: Dominant to £6,084) for etanercept 25 mg biw and £10,351
(£7,056, £15,911) for etanercept 50 mg biw. Cost-effectiveness
was sensitive to the duration of treatment holiday and response
rate after therapy interruption. Cost per QALY gained in patients
with baseline PASI in the range 10–72 and poor quality of life at
baseline has previously been reported to be £3,299 for etanercept
25 mg biw and £10,923 for etanercept 50 mg biw. CONCLU-
SIONS: The model found treatment of a less severe psoriasis
population to be cost-effective. Cost-effectiveness was compa-
rable to ﬁndings in patients with more severe disease and poor
quality of life at baseline.
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OBJECTIVES: To assess the cost-effectiveness of Food for
Special Medical Purposes (FSMP) for the prevention of malnu-
trition in patients undergoing abdominal surgery from the per-
spective of the society in The Netherlands. METHODS: The
costs and beneﬁts of the two treatment strategies were assessed
using a linear decision analytic model reﬂecting treatment pat-
terns and outcomes in abdominal surgery. The model structure
allowed for differences in costs and length of stay. The incremen-
tal cost difference was based on costs associated with cost of
FSMP and hospitalization. Clinical probabilities and resource
utilization were based on clinical trials and published literature;
cost data were from ofﬁcial price tariffs. RESULTS: The use of
FSMP reduces the costs from €3318 to €3066, which corre-
sponds with a €252 (7.6%) cost savings per patient. The addi-
tional costs of FSMP are more than balanced by a reduction on
hospitalization costs. The hospitalization costs reduce from
€3318 to €3044 per patient, which is a 8.3% cost saving and
corresponds with 0.72 days reduction in LOS. The use of FSMP
would lead to an annual cost saving of €40.4 million based on the
number of 160,283 abdominal procedures per year in The Neth-
erlands. Sensitivity analyses were performed on all parameters,
including length of stay and per diem costs. The results showed
that the use of FSMP in all sensitivity analyses remain cost saving
compared to “no use” of FSMP. A threshold analysis on the
length of stay shows that at length of stay of 0.64 days, the use
of FSMP is still cost-effective. CONCLUSIONS: The use of
FSMP is a very cost-effective treatment in The Netherlands and is
dominant over standard care without FSMP: cost savings and
higher effectiveness.
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OF AGGRESSIVE NON-HODGKIN LYMPHOMA (NHL) STAGES
III AND IV:TREATMENT IMPACT OVER RELAPSE AND
SURVIVAL,ATTHE MEXICAN-NATIONAL CANCER
INSTITUTE (MEX-INCAN)
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OBJECTIVES: To perform a CE evaluation of the use of CHOP
vs R-CHOP for the treatment of aggressive NHL stages III
and IV. METHODS: After a review of the medical literature
about the economic impact of NHL treatment, we performed an
analysis of the resources consumed by 116 patients with the
diagnostic of NHL during 2004 in the Mex-INCan. The eco-
nomic evaluation was done using an hypothetical cohort simu-
lation through a ﬁve years by means of Markov Model with
monthly transitions, using a ﬁve percent discount rate. The
model included 11 health status: Diagnostic; 1st-line treatment,
1st-remission, 1st-relapse, 1st-progression, 2nd-line treatment
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